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Pulmonary Tuberculosis Treatment Outcomes in HIV
Infected Patients on Antiretroviral Therapy
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Background: Tuberculosis (TB) is the most common opportunistic
infection (OI) in HIV-infected patients. There are effective regimes
for HIV and TB infection, but the concomitant treatment is diffi-
cult due to adverse effects, drug interaction, and worsening con-
dition. Not all anti-TB drugs are available in developing countries.
This study describes treatment outcomes of pulmonary TB in HIV-
infected patients on antiretroviral therapy (ART).
Materials and Methods: This retrospective study was done at Bam-
rasnaradura Institute, Bangkok. The study was conducted among
TB and HIV co-infected patients, aged 15 years and older, who
received both anti-TB and ART (NNRTI-base). The patients were
admitted in this institute from January 1, 2003 to December 31,
2004.
Results: Sixty-five patients (47 male) with a median age of 32 years
old (range 20-58) was entered into the study. When the TB was
diagnosed, the median CD4 count was 33 cells/ul (range 2-342).
Fifty patients (76.92%) received standard anti-TB (HRZE) regimes
for at least 2 months in the initial phase and fifteen patients
(23.08%) did not receive regimes as above. ART was initiated at
a median of 12 weeks (range 0-52) of TB treatment. Eight patients
(12.3%) had already received ART before the TB diagnosis. Forty-
three (66.1%) and 22 (33.9%) patients received nevirapine (NVP)
and efervirenz (EFV) based regimes, respectively. Thirty-six pa-
tients (55.4%) received NVP and rifampicin (RFP) concurrently, and
the median of overlapping day was 115 (range 5-394). Drug tox-
icity was observed in 26 patients (40%). There was no significant
association between drug toxicity and concurrent use of NVP and
RFP. Five patients (7.7%) had immune reconstitution syndrome and
4 patients (6.2%) had OI after ART. Thirty-three patients (50.8%)
were clinically cured, 20 (30.8%) were cured, 5 (7.7%) were trans-
ferred out, 3(4.6%) had treatment interrupted, 3 (4.6%) died and 1
patient had treatment. There were no associations between treat-
ment outcomes and anti-TB regimes, ART regimes and concurrent
use of NVP and RFP, but initiating ART before or during TB treat-
ment was significantly associated with favorable treatment out-
comes.
Conclusions: Initiation of ART in the early course of HIV infection,
before TB infection, yields a favorable pulmonary TB treatment
outcome. NVP-based ART is an option for HIV-infected patients re-
ceiving RFP. This result is expected to be beneficial for medical
personals involved in HIV patients especially in developing coun-
tries.
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Introduction: The current estimate of the burden of typhoid fever
in Africa is based on population-based studies from Egypt and
South Africa and no estimate is available for invasive non-Typhi
Salmonella (NTS). To gain initial insights into the epidemiology of
invasive salmonellosis in East Africa, we studied febrile admissions
at three hospitals in northern Tanzania.
Methods: We enrolled consecutive febrile patients aged 2 months
to 13 years at Teule District Hospital (TDH), Muheza, and at Kili-
manjaro Christian Medical Centre (KCMC), Moshi, and febrile pa-
tients aged 13 years and above at KCMC and Mawenzi Regional
Hospital (MRH), Moshi. All patients received a standardized clin-
ical history and physical examination, aerobic blood culture, and
HIV antibody testing.
Results: Of 3,664 children admitted to TDH, 319 (8.7%) were bac-
teremic of whom 23 (16%) were HIV antibody-positive on a sin-
gle test, 161(50.5%) had NTS and 9 (2.8%) had S. Typhi blood-
stream infection. Of 33 bacteremic children identified at KCMC,
9 (27%) were HIV-infected, 1 (%) had NTS and 10 (30%) had S. Ty-
phi bloodstream infection. Of 52 bacteremic adults identified at
KCMC and MRH, 20 (39%) were HIV-infected, 5 (9.6%) had NTS and
16 (30.8%) had S. Typhi bloodstream infection. In KCMC and MRH,
NTS bacteremia was associated with HIV seropositivity in all age
groups, 6 patients with NTS were HIV infected, but not with S.Typhi
bacteremia. In TDH, NTS infection was also associated with HIV-
positivity (OR 1.3, p=0.059) but none of the 9 S. Typhi infections
occurred in an HIV-positive child.
Conclusions: The relative importance of S. Typhi and of NTS as
causes of bloodstream infection among febrile, hospitalized pa-
tients varies considerable between two sites in northern Tanzania.
NTS but not S.Typhi bloodstream infection is strongly associated
with HIV infection. Understanding burden of invasive NTS and S. Ty-
phi in Africa requires an approach that addresses considerable epi-
demiologic heterogeneity and that accounts for the influence of
HIV seroprevalence.
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Background: Pediatric antiretroviral therapy is provided in all pri-
mary health care facilities in Cameroon. Despite scale-up of these
perinatal prevention efforts, many children still become infected
with the human immunodeficiency virus (HIV). This study assessed
the impact of antiretroviral therapy (ART) on the clinical and im-
munologic outcomes of children in Cameroon.
S24 Infections in People with HIV
Methods: Patients were children (<15 years old) presenting for
HIV care between February 2005, and March 2007 at five primary
healthcare clinics in South Western Cameroon. Participants who
met the national treatment criteria and gave their informed writ-
ten consent were randomly allocated to receive one of the three
drugs (ARTs) (zidovudine or stavudine plus lamivudine plus nevirap-
ine or efavirenz). The subjects were treated as recommended and
followed up by nurses and medical officers in the various health-
care clinics. During which time, the survival rate, weight gain, CD4
cell count, and haematologic responses were evaluated.
Results: Of 5043 children enrolled into HIV care, 3432 (68.1%)
started ART. Of those initiating ART, the median age was 80 months
(range: 36-125), 2073 (60.4%) were female, and 2542 (74.1%) with
WHO stage information at stage III or later. During analysis, 230
children (6.7%) had withdrawn from care and 421(12.3%) were at
least 30 days late for follow-up. Of the remaining 3432 children
receiving ART, 245 (7.1%) died over 3512 child-years of follow-up
(mortality rate, 7.8 deaths per 100 child-years; 95% confidence in-
terval [CI]: 6.3-8.4); of these deaths, 167 (68.2%) occurred within 3
months of therapy initiation (early mortality rate, 15.7/100 child-
years; post-90-day mortality rate, 3.6/100 child-years). Mortal-
ity was associated with CD4 cell depletion, lower weight-for-age,
younger age, and anemia in multivariate analysis. The mean CD4
cell percentage at ART initiation among the 1897 children who had
at least a repeat measurement was 14.2% (95% CI: 13.3%-15.7%)
and increased to 26.8% (95% CI: 26.0%-27.6%) at 6 months, 29.3%
(95% CI: 28.7%-30.4%) at 12 months, 30.1% (95% CI: 29.7%-30.8%) at
18 months, and 31.2% (95% CI: 30.2%-31.9%) at 24 months.
Conclusions: Care provided by caregivers may result in good clini-
cal and immunologic outcomes for HIV-infected children in primary
health care settings in resource poor settings. Mortality rate dur-
ing the first 3 months of therapy is high, highlighting the need for
earlier intervention in these patients age group.
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Background: In Nigeria, the HIV/AIDS epidemic has reached an
alarming level and more persons get infected on daily basis. One of
the major problems of this epidemic is the opportunistic infections
usually associated to it. With no cure in sight, it has been suggested
that the best practice is to limit the secondary infections as much
as possible. In several developing countries, not many studies have
been conducted to ascertain the level of involvement of some of
these opportunistic pathogens; and where substantial studies have
been carried out, there is need to monitor the trend considering
that in recent times, several new and relatively strange microor-
ganisms have been reportedly isolated from similar patients.
Objectives: To ascertain the prevalence of secondary fungal infec-
tions in HIV/AIDS patients in Nigeria at the moment and the suscep-
tibility of the isolates to some conventional and non-conventional
(ethanolic medicinal plant extracts) antifungal agents. These
medicinal plant extracts, though in use by some patients, have
not been tested against isolates obtained directly from HIV/AIDS
patients.
Methods: Oral and nasal swabs collected from different categories
of HIV/AIDS patients attending different hospitals and samples
were plated on general purpose medium for fungi. Relevant subcul-
tures were made and identified. MICs of the antimicrobial agents
were determined following the CLSI guidelines. Prior to this, some
of the medicinal plants collected from the patients were identified
and prepared using standard methods.
Results: Several fungal isolates viz: Candida albicans and Non-
albicans Candida species which showed similar prevalence, fol-
lowed by Aspergillus, Cryptococcus, Histoplasma and Scedospo-
rium species. Other rare fungal species not previously reported in
our patients had a total prevalence of 20%.They were mainly envi-
ronmental pathogens which may have evolved by ecological shift.
Compared to our previous data, resistance is still on the increase.
However, medicinal plant extracts showed promising activities on
some of the isolates which were hitherto resistant to some of the
conventional agents.
Conclusions: Some new organisms are increasingly getting involved
as secondary pathogens in HIV/AIDS patients in Nigeria. There is
need to continue to monitor and report the trend so as to assist
clinicians in handling these patients.
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Background: Nucleoside RT inhibitors (NRTIs) are among the most
potent anti-HIV agents. All approved NRTIs act as chain terminators
because they lack a 3' OH, and it has long been considered that the
absence of the 3' OH is essential for antiviral activity. However, this
feature can also impart detrimental properties to the inhibitor,
such as reduced affinity for RT compared to the analogous dNTP
substrate, as well as reduced intracellular conversion to the active
nucleoside triphosphate. In an effort to overcome this problem,
it was shown that certain nucleosides that retain the 3' OH group
and have substitutions at the 4' of the deoxyribose sugar and 2
position of the base have exceptional antiviral properties. One of
these compounds, 4' -ethynyl, 2-fluoro deoxy-adenosine (4' E-2FdA)
is the most potent NRTI inhibitor against wild-type and mutant re-
sistant HIV viruses described to date. We have recently reported
that 4' E-2FdA acts as a chain terminator despite the presence of
an accessible 3' OH.
Objectives: Our goal is to characterize inhibitors that have a 3'
OH group, but have a modification at their 4' position and identify
their mechanism of action.
Methods: The behaviour of RT in the presence of the 4' modi-
fied nucleotide analog was studied using enzymology assays such
as primer extension and gel mobility shift assays.
Results: We report here the molecular mechanism of action of
this unusual inhibitor. We show that after 4' E-2FdA-MP incorpo-
ration, RT is unable to bind the next incoming dNTP. We analyzed
the translocation status of RT on different sequences terminated
with 4' E-2FdA-MP, and found that even at sequences when RT is
naturally found post-translocated, the inhibitor prevents transloca-
tion. This decrease in translocation efficiency explains the reduced
binding of the next incoming dNTP and the termination of elon-
